Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (447) 447
Conference Proceeding (5) 5
Publication (4) 4
Book Review (3) 3
Magazine Article (3) 3
Book Chapter (2) 2
Government Document (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (276) 276
science & technology (252) 252
life sciences & biomedicine (245) 245
female (182) 182
male (175) 175
child (147) 147
adolescent (123) 123
child, preschool (120) 120
diabetes (114) 114
type 1 diabetes (113) 113
biological and medical sciences (105) 105
medical sciences (104) 104
endocrinology & metabolism (98) 98
adult (95) 95
abridged index medicus (83) 83
infant (82) 82
medical and health sciences (69) 69
medicin och hälsovetenskap (69) 69
autoantibodies (68) 68
risk factors (67) 67
clinical medicine (64) 64
klinisk medicin (62) 62
children (61) 61
research (61) 61
middle aged (57) 57
diabetes mellitus, type 1 - immunology (55) 55
pediatrics (55) 55
clinical trials (52) 52
endocrinology and diabetes (52) 52
endokrinologi och diabetes (52) 52
diabetes mellitus (51) 51
autoimmunity (48) 48
prospective studies (46) 46
diabetes mellitus, type 1 - genetics (43) 43
endocrinopathies (42) 42
diabetes. impaired glucose tolerance (41) 41
endocrine pancreas. apud cells (41) 41
health aspects (39) 39
young adult (39) 39
insulin (38) 38
etiopathogenesis. screening. investigations. target tissue resistance (36) 36
follow-up studies (35) 35
autoantibodies - blood (34) 34
diabetes mellitus, type 1 - prevention & control (34) 34
care and treatment (32) 32
disease progression (32) 32
infant, newborn (32) 32
islets of langerhans - immunology (32) 32
prevention (32) 32
aged (30) 30
medical research (30) 30
oncology (30) 30
metabolic diseases (29) 29
analysis (28) 28
diabetes mellitus, type 1 - epidemiology (28) 28
epidemiology (27) 27
age (26) 26
development and progression (26) 26
chemotherapy (25) 25
general & internal medicine (25) 25
genetic predisposition to disease (25) 25
histocompatibility antigen hla (25) 25
risk (25) 25
cohort studies (24) 24
diabetes mellitus, type 1 - blood (24) 24
genotype (24) 24
glucose tolerance test (23) 23
autoantibodies - immunology (22) 22
diabetes mellitus, type 1 - diagnosis (22) 22
glucose (22) 22
peptides (22) 22
studies (22) 22
united states (22) 22
diagnosis (21) 21
double-blind method (21) 21
pharmacology. drug treatments (21) 21
prognosis (21) 21
public health. hygiene (21) 21
public health. hygiene-occupational medicine (21) 21
original research (20) 20
usage (20) 20
antineoplastic agents (19) 19
diabetes mellitus, type 1 - metabolism (19) 19
glutamate decarboxylase (19) 19
miscellaneous (19) 19
genetic aspects (18) 18
glutamate decarboxylase - immunology (18) 18
health risk assessment (18) 18
medicine, experimental (18) 18
proportional hazards models (18) 18
diabetes mellitus, type 1 - etiology (17) 17
immunology (17) 17
medicine, general & internal (17) 17
pancreas (17) 17
autoimmune diseases (16) 16
children & youth (16) 16
diabetes mellitus, type 1 - pathology (16) 16
genotypes (16) 16
incidence (16) 16
medicine, research & experimental (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
by McCormack, Francis X and Inoue, Yoshikazu and Moss, Joel and Singer, Lianne G and Strange, Charlie and Nakata, Koh and Barker, Alan F and Chapman, Jeffrey T and Brantly, Mark L and Stocks, James M and Brown, Kevin K and Lynch, Joseph P and Goldberg, Hilary J and Young, Lisa R and Kinder, Brent W and Downey, Gregory P and Sullivan, Eugene J and Colby, Thomas V and McKay, Roy T and Cohen, Marsha M and Korbee, Leslie and Taveira-DaSilva, Angelo M and Lee, Hye-Seung and Krischer, Jeffrey P and Trapnell, Bruce C and Natl Inst Hlth Rare Lung Dis Conso and MILES Trial Grp and MILES Trial Group and National Institutes of Health Rare Lung Diseases Consortium
The New England journal of medicine, ISSN 0028-4793, 04/2011, Volume 364, Issue 17, pp. 1595 - 1606
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Sirolimus - therapeutic use | Double-Blind Method | Forced Expiratory Volume - drug effects | Humans | Lymphangioleiomyomatosis - physiopathology | Middle Aged | Lymphangioleiomyomatosis - drug therapy | Sirolimus - blood | TOR Serine-Threonine Kinases - antagonists & inhibitors | Vital Capacity - drug effects | Medication Adherence | Intention to Treat Analysis | Observation | Quality of Life | Adult | Female | Sirolimus - adverse effects | Diagnosis | Drug therapy | Lung diseases | Patient outcomes | Human subjects | Lungs | Kinases | Womens health | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial
by Young, Lisa R and Lee, Hye-Seung and Inoue, Yoshikazu and Moss, Joel and Singer, Lianne G and Strange, Charlie and Nakata, Koh and Barker, Alan F and Chapman, Jeffrey T and Brantly, Mark L and Stocks, James M and Brown, Kevin K and Lynch, Joseph P and Goldberg, Hilary J and Downey, Gregory P and Swigris, Jeffrey J and Taveira-DaSilva, Angelo M and Krischer, Jeffrey P and Trapnell, Bruce C and McCormack, Francis X and MILES Trial Grp and MILES Trial Group
The lancet respiratory medicine, ISSN 2213-2600, 08/2013, Volume 1, Issue 6, pp. 445 - 452
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Biomarkers - metabolism | Lung Neoplasms - drug therapy | Lymphangioleiomyomatosis - blood | Sirolimus - therapeutic use | Prospective Studies | Double-Blind Method | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Lymphangioleiomyomatosis - drug therapy | Vital Capacity - drug effects | Young Adult | Vascular Endothelial Growth Factor D - metabolism | Antibiotics, Antineoplastic - therapeutic use | Adult | Female | Aged | Lung Neoplasms - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial–Type 1
by Jay M. Sosenko and Jeffrey P. Krischer and Jerry P. Palmer and Jeffrey Mahon and Catherine Cowie and Carla J. Greenbaum and David Cuthbertson and John M. Lachin and Jay S. Skyler and the Diabetes Prevention Trial–Type 1 Study Group and Diabet Prevention Trial-Type 1 Stu and Diabetes Prevention Trial-Type 1 Study Group and the Diabetes Prevention Trial-Type 1 Study Group
Diabetes care, ISSN 0149-5992, 03/2008, Volume 31, Issue 3, pp. 528 - 533
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Hypoglycemic Agents - therapeutic use | Glucose Tolerance Test | Prognosis | Blood Glucose - analysis | C-Peptide - blood | Diabetes Mellitus, Type 1 - prevention & control | Autoantibodies - blood | Humans | Middle Aged | Risk Factors | Child, Preschool | Islets of Langerhans - immunology | Diabetes Mellitus, Type 1 - diagnosis | Regression Analysis | Diabetes Mellitus, Type 1 - blood | Adolescent | Adult | Child | Insulin - therapeutic use | Cohort Studies | Autoimmunity | Prevention | Autoantibodies | Type 1 diabetes | Models | Glucose | Research | Dextrose | Intervention | Studies | Hyperglycemia | Diabetes | Health risk assessment | Risk factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
by Herold, Kevan C and Bundy, Brian N and Long, S. Alice and Bluestone, Jeffrey A and DiMeglio, Linda A and Dufort, Matthew J and Gitelman, Stephen E and Gottlieb, Peter A and Krischer, Jeffrey P and Linsley, Peter S and Marks, Jennifer B and Moore, Wayne and Moran, Antoinette and Rodriguez, Henry and Russell, William E and Schatz, Desmond and Skyler, Jay S and Tsalikian, Eva and Wherrett, Diane K and Ziegler, Anette-Gabriele and Greenbaum, Carla J and Type 1 Diabet TrialNet Study Grp and Type 1 Diabetes TrialNet Study Group
The New England journal of medicine, ISSN 0028-4793, 08/2019, Volume 381, Issue 7, pp. 603 - 613
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Glucose Tolerance Test | Antibodies, Monoclonal, Humanized - therapeutic use | Diabetes Mellitus, Type 1 - prevention & control | Double-Blind Method | CD3 Complex - antagonists & inhibitors | Humans | Middle Aged | Proportional Hazards Models | Diabetes Mellitus, Type 1 - genetics | Male | Disease Progression | Young Adult | HLA-DR3 Antigen | Exanthema - chemically induced | Adolescent | HLA-DR4 Antigen | Lymphocyte Count | Adult | Female | T-Lymphocytes - immunology | Diabetes Mellitus, Type 1 - immunology | Child | Lymphopenia - chemically induced | Diabetics | Care and treatment | Usage | Safety and security measures | Type 1 diabetes | Monoclonal antibodies | Development and progression | Drug therapy | Risk factors | Laboratories | CD8 antigen | Clinical trials | Lymphocytes T | Diabetes mellitus (insulin dependent) | Glucose | Hyperglycemia | Diagnosis | Drug dosages | Age | Cell survival | Diabetes mellitus | CD3 antigen | Metabolism | Insulin | KLRG1 protein | Immunological tolerance | Zinc transporter | Beta cells | Glucose tolerance | Fc receptors | Lymphopenia | Histocompatibility antigen HLA | Diabetes | Autoimmune diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The use of intermediate endpoints in the design of type 1 diabetes prevention trials
by Krischer, Jeffrey P and Type 1 Diabetes TrialNet Study Group and the Type 1 Diabetes TrialNet Study Group
Diabetologia, ISSN 0012-186X, 9/2013, Volume 56, Issue 9, pp. 1919 - 1924
Intermediate endpoints | Prevention | Dysglycaemia | Medicine & Public Health | Human Physiology | HbA 1c | Type 1 diabetes | C-peptide | Metabolic Diseases | Internal Medicine | Clinical trial | HbA | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Diabetes. Impaired glucose tolerance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Autoantibodies - metabolism | Glucose Tolerance Test | Diabetes Mellitus, Type 1 - prevention & control | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Child, Preschool | Diabetes Mellitus, Type 1 - metabolism | Infant | Male | Young Adult | Diabetes Mellitus, Type 1 - blood | Adolescent | Adult | Female | Blood Glucose - metabolism | C-Peptide - metabolism | Child | Clinical trials | Usage | Index Medicus | HbA1c
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
by Sosenko, Jay M and Skyler, Jay S and Palmer, Jerry P and Krischer, Jeffrey P and Yu, Liping and Mahon, Jeffrey and Beam, Craig A and Boulware, David C and Rafkin, Lisa and Schatz, Desmond and Eisenbarth, George and Diabet Prevention Trial-Type 1 Stu and Type 1 Diabetes TrialNet Grp and Type 1 Diabetes TrialNet Study Group and Diabetes Prevention Trial-Type 1 Study Group and the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial–Type 1 Study Groups
Diabetes care, ISSN 0149-5992, 09/2013, Volume 36, Issue 9, pp. 2615 - 2620
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Young Adult | Autoantibodies - immunology | Humans | Risk Factors | Adolescent | Child, Preschool | Adult | Female | Male | Diabetes Mellitus, Type 1 - immunology | Child | Autoimmunity | Diabetics | Care and treatment | Autoantibodies | Type 1 diabetes | Risk factors | Disease prevention | Diabetes | Medical screening | Health risk assessment | Polyclonal antibodies | Predictions | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
by Tihamer Orban and Jay M. Sosenko and David Cuthbertson and Jeffrey P. Krischer and Jay S. Skyler and Richard Jackson and Liping Yu and Jerry P. Palmer and Desmond Schatz and George Eisenbarth and for the Diabetes Prevention Trial–Type 1 Study Group and Diabet Prevention Trial Type 1 Stu and Diabetes Prevention Trial-Type 1 Study Group and for the Diabetes Prevention Trial-Type 1 Study Group
Diabetes care, ISSN 0149-5992, 12/2009, Volume 32, Issue 12, pp. 2269 - 2274
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Diabetes Mellitus, Type 1 - enzymology | Predictive Value of Tests | Receptor-Like Protein Tyrosine Phosphatases, Class 8 - immunology | Prospective Studies | Diabetes Mellitus, Type 1 - prevention & control | Humans | Islets of Langerhans - immunology | Diabetes Mellitus, Type 1 - diagnosis | Autoantibodies - analysis | Surveys and Questionnaires | Diabetes Mellitus, Type 1 - immunology | Glutamate Decarboxylase - immunology | Cohort Studies | Prevention | Autoimmunity | Cell research | Autoantibodies | Type 1 diabetes | Development and progression | Glutamate decarboxylase | Research | Diabetes | Health surveys | Disease prevention | Clinical trials | Pancreas | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial
by Wherrett, Diane K, MD and Bundy, Brian, PhD and Becker, Dorothy J, Prof and DiMeglio, Linda A, MD and Gitelman, Stephen E, Prof and Goland, Robin, Prof and Gottlieb, Peter A, Prof and Greenbaum, Carla J, MD and Herold, Kevan C, Prof and Marks, Jennifer B, Prof and Monzavi, Roshanak, MD and Moran, Antoinette, Prof and Orban, Tihamer, MD and Palmer, Jerry P, MD and Raskin, Philip, Prof and Rodriguez, Henry, Prof and Schatz, Desmond, Prof and Wilson, Darrell M, Prof and Krischer, Jeffrey P, Prof and Skyler, Jay S, Dr, Prof and the Type 1 Diabetes TrialNet GAD Study Group and Type 1 Diabet TrialNet GAD Study G and Type 1 Diabetes TrialNet GAD Study Group
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9788, pp. 319 - 327
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Double-Blind Method | United States | Humans | Middle Aged | Autoimmune Diseases - immunology | Child, Preschool | Immunotherapy, Active | Male | Diabetes Mellitus, Type 1 - therapy | Young Adult | Canada | Antigens - therapeutic use | Glutamate Decarboxylase - therapeutic use | Adolescent | Autoimmune Diseases - therapy | Antigens - immunology | Female | Diabetes Mellitus, Type 1 - immunology | Glutamate Decarboxylase - immunology | Child | Prevention | Glutamate decarboxylase | Vaccines | Type 1 diabetes | Health aspects | Clinical trials | Data collection | Lines of credit | Diabetes | Pharmaceuticals | Aluminum hydroxide | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
by Orban, Tihamer, MD and Bundy, Brian, PhD and Becker, Dorothy J, Prof and DiMeglio, Linda A, MD and Gitelman, Stephen E, Prof and Goland, Robin, Prof and Gottlieb, Peter A, Prof and Greenbaum, Carla J, MD and Marks, Jennifer B, Prof and Monzavi, Roshanak, MD and Moran, Antoinette, Prof and Raskin, Philip, Prof and Rodriguez, Henry, Prof and Russell, William E, Prof and Schatz, Desmond, Prof and Wherrett, Diane, MD and Wilson, Darrell M, Prof and Krischer, Jeffrey P, Prof and Skyler, Jay S, Dr, Prof and the Type 1 Diabetes TrialNet Abatacept Study Group and Type 1 Diabet TrialNet Abatacept S and Type 1 Diabetes TrialNet Abatacept Study Group
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9789, pp. 412 - 419
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Autoimmunity | Insulin-Secreting Cells - physiology | Double-Blind Method | Diabetes Mellitus, Type 1 - physiopathology | Humans | Immunosuppressive Agents - therapeutic use | Male | Diabetes Mellitus, Type 1 - drug therapy | Randomized Controlled Trials as Topic | Immunoconjugates - immunology | Young Adult | Abatacept | Adolescent | Immunoconjugates - therapeutic use | Adult | Female | Immunosuppressive Agents - adverse effects | T-Lymphocytes - immunology | Diabetes Mellitus, Type 1 - immunology | Child | Immunoconjugates - adverse effects | Type 1 diabetes | Physiological aspects | Research | Drug therapy | T cells | Health aspects | Risk factors | Clinical trials | Hepatitis | Diabetes | Peptides | Rheumatoid arthritis | Embargoes & blockades | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights